Trial · NCT03004469
Results by group102
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 102
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Adjusted Mean Change From Baseline in Hair Growth Assessed by Target Area Hair Count (TAHC) in the Vertex at Week 24 | P-3074 + Finasteride Placebo | 20.2 | Standard Deviation 2.88 | Hairs | |
| Adjusted Mean Change From Baseline in Hair Growth Assessed by Target Area Hair Count (TAHC) in the Vertex at Week 24 | P-3074 Vehicle + Finasteride Placebo | 6.7 | Standard Deviation 3.01 | Hairs | |
| Adjusted Mean Change From Baseline in Hair Growth Assessed by Target Area Hair Count (TAHC) in the Vertex at Week 24 | Oral Finasteride + P-3074 Vehicle | 21.1 | Standard Deviation 3.90 | Hairs | |
| Adjusted Mean Change From Baseline in Hair Growth Assessed by TAHC in the Vertex at Week 12 | P-3074 + Finasteride Placebo | 20.4 | Standard Deviation 2.41 | Hairs | |
| Adjusted Mean Change From Baseline in Hair Growth Assessed by TAHC in the Vertex at Week 12 | P-3074 Vehicle + Finasteride Placebo | 7.6 | Standard Deviation 2.46 | Hairs | |
| Adjusted Mean Change From Baseline in Hair Growth Assessed by TAHC in the Vertex at Week 12 | Oral Finasteride + P-3074 Vehicle | 22.5 | Standard Deviation 3.31 | Hairs | |
| Adjusted Mean Change From Baseline in Target Area Hair Width (TAHW) in the Vertex at Weeks 12 and 24 | P-3074 + Finasteride Placebo | Week 12 | -1.1231 | Standard Deviation 0.30653 | Micrometer |
| Adjusted Mean Change From Baseline in Target Area Hair Width (TAHW) in the Vertex at Weeks 12 and 24 | P-3074 Vehicle + Finasteride Placebo | Week 12 | -0.7207 | Standard Deviation 0.31033 | Micrometer |
| Adjusted Mean Change From Baseline in Target Area Hair Width (TAHW) in the Vertex at Weeks 12 and 24 | Oral Finasteride + P-3074 Vehicle | Week 12 | -0.6938 | Standard Deviation 0.41951 | Micrometer |
| Adjusted Mean Change From Baseline in Target Area Hair Width (TAHW) in the Vertex at Weeks 12 and 24 | P-3074 + Finasteride Placebo | Week 24 | -0.8052 | Standard Deviation 0.35151 | Micrometer |
| Adjusted Mean Change From Baseline in Target Area Hair Width (TAHW) in the Vertex at Weeks 12 and 24 | P-3074 Vehicle + Finasteride Placebo | Week 24 | -1.5289 | Standard Deviation 0.36691 | Micrometer |
| Adjusted Mean Change From Baseline in Target Area Hair Width (TAHW) in the Vertex at Weeks 12 and 24 | Oral Finasteride + P-3074 Vehicle | Week 24 | 0.7163 | Standard Deviation 0.46679 | Micrometer |
| Adjusted Mean Overall Male Hair Growth Questionnaire (MHGQ) Score as Assessed by the Participant at Weeks 12 and 24 | P-3074 + Finasteride Placebo | Week 12 | 2.9 | Standard Error 0.08 | score on a scale |
| Adjusted Mean Overall Male Hair Growth Questionnaire (MHGQ) Score as Assessed by the Participant at Weeks 12 and 24 | P-3074 Vehicle + Finasteride Placebo | Week 12 | 3.0 | Standard Error 0.09 | score on a scale |
| Adjusted Mean Overall Male Hair Growth Questionnaire (MHGQ) Score as Assessed by the Participant at Weeks 12 and 24 | Oral Finasteride + P-3074 Vehicle | Week 12 | 2.8 | Standard Error 0.12 | score on a scale |
| Adjusted Mean Overall Male Hair Growth Questionnaire (MHGQ) Score as Assessed by the Participant at Weeks 12 and 24 | P-3074 + Finasteride Placebo | Week 24 | 2.8 | Standard Error 0.09 | score on a scale |
| Adjusted Mean Overall Male Hair Growth Questionnaire (MHGQ) Score as Assessed by the Participant at Weeks 12 and 24 | P-3074 Vehicle + Finasteride Placebo | Week 24 | 3.0 | Standard Error 0.10 | score on a scale |
| Adjusted Mean Overall Male Hair Growth Questionnaire (MHGQ) Score as Assessed by the Participant at Weeks 12 and 24 | Oral Finasteride + P-3074 Vehicle | Week 24 | 2.9 | Standard Error 0.13 | score on a scale |
| Adjusted Mean Change From Baseline in Participants Hair Growth/Loss Assessed for the Vertex by Investigator at Weeks 12 and 24 | P-3074 + Finasteride Placebo | Week 12 | 0.5 | Standard Error 0.10 | score on a scale |
| Adjusted Mean Change From Baseline in Participants Hair Growth/Loss Assessed for the Vertex by Investigator at Weeks 12 and 24 | P-3074 Vehicle + Finasteride Placebo | Week 12 | 0.4 | Standard Error 0.11 | score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03004469/results